LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | Torin1 | 3.33 | uM | LJP6 | 3 | O14 | 72 | hr | 513 | 1006 | 10401 | 0.0967 | 0.0498 |
MCF 10A | Torin2 | 3.33 | uM | LJP5 | 1 | I20 | 72 | hr | 513 | 527 | 10401 | 0.0507 | 0.0014 |
MCF 10A | Torin2 | 3.33 | uM | LJP5 | 2 | I20 | 72 | hr | 513 | 449 | 10401 | 0.0432 | -0.0065 |
MCF 10A | Torin2 | 3.33 | uM | LJP5 | 3 | I20 | 72 | hr | 513 | 611 | 10401 | 0.0587 | 0.0099 |
MCF 10A | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 513 | 803 | 10401 | 0.0772 | 0.0293 |
MCF 10A | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 513 | 775 | 10401 | 0.0745 | 0.0265 |
MCF 10A | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 513 | 1095 | 10401 | 0.1053 | 0.0588 |
MCF 10A | Trametinib | 3.33 | uM | LJP5 | 1 | P20 | 72 | hr | 513 | 932 | 10401 | 0.0896 | 0.0423 |
MCF 10A | Trametinib | 3.33 | uM | LJP5 | 2 | P20 | 72 | hr | 513 | 851 | 10401 | 0.0818 | 0.0341 |
MCF 10A | Trametinib | 3.33 | uM | LJP5 | 3 | P20 | 72 | hr | 513 | 948 | 10401 | 0.0911 | 0.0440 |
MCF 10A | TWS119 | 3.33 | uM | LJP5 | 1 | M02 | 72 | hr | 513 | 6641 | 10401 | 0.6385 | 0.6197 |
MCF 10A | TWS119 | 3.33 | uM | LJP5 | 2 | M02 | 72 | hr | 513 | 6381 | 10401 | 0.6135 | 0.5934 |
MCF 10A | TWS119 | 3.33 | uM | LJP5 | 3 | M02 | 72 | hr | 513 | 6291 | 10401 | 0.6048 | 0.5843 |
MCF 10A | Vemurafenib | 3.33 | uM | LJP5 | 1 | C14 | 72 | hr | 513 | 3867 | 10401 | 0.3718 | 0.3392 |
MCF 10A | Vemurafenib | 3.33 | uM | LJP5 | 2 | C14 | 72 | hr | 513 | 4101 | 10401 | 0.3943 | 0.3628 |
MCF 10A | Vemurafenib | 3.33 | uM | LJP5 | 3 | C14 | 72 | hr | 513 | 5325 | 10401 | 0.5120 | 0.4866 |
MCF 10A | Withaferin A | 3.33 | uM | LJP5 | 1 | G14 | 72 | hr | 513 | 355 | 10401 | 0.0341 | -0.0160 |
MCF 10A | Withaferin A | 3.33 | uM | LJP5 | 2 | G14 | 72 | hr | 513 | 405 | 10401 | 0.0389 | -0.0110 |
MCF 10A | Withaferin A | 3.33 | uM | LJP5 | 3 | G14 | 72 | hr | 513 | 364 | 10401 | 0.0350 | -0.0151 |
MCF 10A | Withaferin A | 3.33 | uM | LJP6 | 1 | G14 | 72 | hr | 513 | 290 | 10401 | 0.0279 | -0.0226 |
MCF 10A | Withaferin A | 3.33 | uM | LJP6 | 2 | G14 | 72 | hr | 513 | 369 | 10401 | 0.0355 | -0.0146 |
MCF 10A | Withaferin A | 3.33 | uM | LJP6 | 3 | G14 | 72 | hr | 513 | 377 | 10401 | 0.0362 | -0.0138 |
MCF 10A | WYE-125132 | 3.33 | uM | LJP6 | 1 | L08 | 72 | hr | 513 | 917 | 10401 | 0.0882 | 0.0408 |
MCF 10A | WYE-125132 | 3.33 | uM | LJP6 | 2 | L08 | 72 | hr | 513 | 903 | 10401 | 0.0868 | 0.0394 |
MCF 10A | WYE-125132 | 3.33 | uM | LJP6 | 3 | L08 | 72 | hr | 513 | 869 | 10401 | 0.0835 | 0.0360 |